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Medication in relation to complications after 
endovascular abdominal aortic aneurysm repair
Medicagoes referentes as complicagoes após corregao de aneurisma da aorta abdominal endovascular
Giel G. KONING, Roel HOBO, Robert J. F. LAHEIJ, Jacob BUTH, J. Adam VAN DER VLIET
RBCCV 44205-810
Abstract
Objective: This observational study was undertaken to 
explore the influence of medication on the occurrence of 
complications following endovascular repair of abdominal 
aortic aneurysms.
Methods: Clinical data concerning 70 consecutive patients 
undergoing elective EVAR in two vascular surgical centres 
over a 3 year period were analysed retrospectively. 
Complications were graded according to the recommendations 
of the Ad Hoc Committee on Reporting Standards. A 
distinction was made between device-related and non-related 
complications. An adjusted regression analysis was used to 
assess the association between 12 different medication groups 
and EVAR outcome.
Results: During 70 person years of follow-up 14 mild (20%), 
23 moderate (33%) and 7 severe (10%) complications were 
recorded. Thirty patients (43%) who used coumarin derivates 
showed significantly less non-device-related complications
(OR 0.21; 95%CI 0.05-0.90) compared to non-users. Twenty 
patients (29%) on anti-emetic drugs during hospital stay 
showed a fourfold more non-device-related complications (OR 
4.37; 95%CI 1.10-17.3) and in-hospital use of analgesics in 
25 patients was associated with m ore device-related  
complications (OR 3.81; 95%CI 1.32-11.0).
Conclusion: Medication seems to be associated with the 
occurrence of complications following endovascular therapy 
of abdominal aortic aneurysms. Patients who used coumarin- 
derivatives experienced few er non-device-related  
complications. Patients who used anti-emetic drugs during 
hospital-stay showed a fourfold number of non-device-related 
complications. Patients using analgesics during hospital stay 
were associated with significantly more device-related  
complications
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Vascular surgical procedures. Stents, complications.
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Resumo
Objetivo: Este estudo observacional foi desenvolvido para 
pesquisar a influencia dos medicamentos na ocorrência de 
com plicares após corregao endovascular de aneurismas da 
aorta abdominal.
Método: Foram analisados retrospectivamente os dados 
clínicos referentes a 70 pacientes consecutivos submetidos a 
corregao endovascular de aneurisma da aorta abdominal em 
dois centros cirúrgicos vasculares num período de 3 anos. As 
co m p lic a r e s  eram classificadas de acordo com as 
re co m en d a res  do Comité Designado de Padroes de 
Tratamento. Foi feita uma d is t in to  entre com plicares  
relacionadas ou nao ao stent. Uma análise de regressao foi 
usada para avaliar a associatao entre 12 grupos de 
m edicam entos d iferentes e o resultado da corregao  
endovascular.
Resultados: Durante um acompanhamento de 70 pacientes- 
anos, foram relatadas 14 complicates leves (20%), 23 moderadas 
(33%) e sete graves (10%). Trinta pacientes (43%) que usaram 
cumarínicos tiveram significantemente menos complicares nao
relacionadas ao stent (OR. 0,21; 95% CI 0,05-0,90) comparados 
com os nao usuarios. V inte pacientes (29%), tomando 
medicamentos antieméticos durante internado, mostraram 
quatro vezes mais complicares relacionadas ao stent (OR. 4,37; 
95% CI 1,10-17,3) e o uso de analgésicos no hospital em 25 
pacientes foi associado com mais complicares relacionadas ao 
stent (OR. 3,81; 95% CI 1,32-11,0).
Conclusao: Medica^oes parecem estar associados com a 
ocorrência de com plicares após terapia endovascular de 
aneurismas da aorta abdominal. Pacientes que usaram  
cumarínicos tiveram menos com plicares nao relacionadas 
ao stent. Pacientes que usaram agentes antieméticos durante 
internado mostraram um número quatro vezes maior de 
com plicares nao relacionadas ao stent. Pacientes usando 
analgésicos durante a in tern ad o  eram associados com 
maiores com plicares relacionadas ao stent.
Descritores: Aneurisma da aorta abdominal, complicares. 
Procedim entos cirúrgicos vasculares. Contenedores,
complicares.
INTRODUCTION
Co-morbidity is common in patients with abdominal 
aortic aneurysms (AAA) [1]. The majority of AAA-patients 
have manifestations of cardiovascular disease such as 
myocardial infarction, stroke or hypertension, as well as 
pulmonary problems [2-4]. These co-morbidities require 
several medication-controlled treatments at the same time. 
The importance of medication in the prevention of secondary 
events is well known [5], but there is a risk of side effects or 
interaction of drugs in patients undergoing endovascular 
aneurysm repair (EVAR).
The reported incidence of complications after EVAR 
varies from 20% to 75% [6]. This morbidity is considerable 
and requires further investigation [6]. While in the earlier 
series complications could be attributed to suboptimal 
device construction, present stent-graft and delivery 
systems have improved and are fairly standardised [7]. 
With the use of improved equipment, the patient and 
doctor related risk factors for failure or complications are 
becoming more important determinants [6,8,9]. These 
factors have not been very well defined at the present 
time [6]. Various conditions may be expected to influence 
the occurrence of complications such as the learning 
curve, and anatomic characteristics of the aneurysm 
[10,11]. Also patient factors such as age, ASA-class and 
medication may influence the occurrence of complications
and prolong hospital stay [2,6].
Until now, no research has been carried out on the 
influence of medication side effects or interactions on the 
occurrence of complications in AAA-patients with 
endovascular aneurysm repair.
METHOD
Subjects
Patients with endovascular abdominal aneurysm repair 
(EVAR) or attempted EVAR between April 1999 and 
November 2003 in two vascular surgical centres were 
included in the study. Experienced surgeons and 
interventional radiologists jointly performed implantation 
of stent-grafts. When necessary, adjuvant procedures such 
as the placement of extension devices of iliac limbs, coil 
embolisation of side branches, endarterectomy or patch­
plasty of the common femoral artery were performed to obtain 
a satisfactory result. All patients were placed in the intensive 
care unit for monitoring during the first 4-20 hours after 
EVAR. On the first post-operative day, patients started with 
acetylsalicyl-acid (ASA) at a dosage of 80-100 mg per day 
as a standard medication. The follow-up protocol included 
contrast-enhanced CT-scanning on the first postoperative 
day and at 6, 12, 18, 24 months and annually thereafter.
Data assessment
Treatment results were assessed by clinical examination
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and by imaging studies of the vascular morphology and 
endograft during follow-up.In case of death, details of this 
event were recorded as they occurred.
Medication was assessed from medical records. To 
obtain the influence of medication on the occurrence of 
complications, we studied groups of drug as they were used 
by our patients, such as coumarin derivatives, P-blockers, 
calcium-antagonists, thiazide-diuretics and lipid lowering 
medication. Complications were also assessed from medical 
files and verified thereafter. They were classified into device 
related (such as rupture or endoleak type I or III) or non­
device- related (such as endoleak type II or myocardial 
infarction) complications according to the SVS-ISCVS-score. 
Explicit probability of causes of complications was 
determined. All radiological investigations where therefore 
reviewed by a vascular surgeon and a radiologist and were 
judged whether technical satisfaction was obtained. The 
combination of duplex ultrasound-scan (DU S) and computed 
tomographic-angiography (CTA) allowed accurate 
identification of any endoleak source (type I-IV).
Covariates
The study variables included patient characteristics 
such as smoking, obesity, ASA-class, hypertension and co­
morbidity according to the SVS-ISCVS risk score, as well as 
stentgraft type.
Data analysis
Chi-square analysis was used to compare the baseline 
characteristics of the subjects. Rates and relative risks were 
calculated by means of the number of complications in each 
patient-category. To quantify the correlation between clinical 
variables, medication, complications and mortality a logistic 
regression and Cox proportional hazards model was 
constructed. a  of 0.05 was used to define statistical 
significance. All analyses were performed with The SAS 
system (version 8.00, SAS Institute, Cary, NC, USA).
RESULTS
The population consisted of 70 patients of which 66 were 
male. The mean age was 71.8 years (SD: 8.1, Range: 41-86) 
and the average aneurysm diameter was 62.5mm (SD: 10.3, 
Range: 50-110). The mean hospital stay was 4.1 days (SD: 4.9 
Range: 0-31) and mean follow up 9.9 months (SD: 11.9, Range: 
0-37). Eight patients (11%) were classified as ASA class I, 20 
patients ASA class II (29%), 34 ASA class III (49%) and 8 
ASA class IV (11%). Smoking was encountered in 28 patients 
(26%), hypertension in 36 (51%) and 11 patients were obese 
(16%). All operative procedures were planned for non-ruptured 
asymptomatic aneurysms. The mean duration of operation 
was 163 minutes (SD: 52.7 Range: 90-320) (Table 1).
Table 1. Patient demographics.
Age Mean (SD)
Aneurysm diameter 71.8 years (8.1)
Procedure duration 62.5 mm (10.3)
Hospital stay 163 min (52.7)
Length of follow-up 4.1 days (4.9)
9.9 months (11.9)
Smoking n (%)
Hypertension 28 (26)
Obesity 36 (51)
ASA Class 11 (16) 
1 8 (11)
2 20 (29)
3 34 (49)
4 8 (11)
Overall, 41 patients (59%) experienced one or more 
complications (N=67) of which 24 were device-related and 
43 non-device-related complications (Table 2). Most 
complications were in the early post-operative period. There 
were 20 endoleaks (29%) of which 8 were type I (11%), 4 
endoleaks type II (6%), 4 endoleaks type III (6%), 0 type IV 
and 4 unspecified endoleaks (6%). No stent-graft infections 
or AAA-ruptures were encountered. Four patients died 
postoperatively (6%) of which two due to a malignancy 
after 2 months, one due to a pulmonary embolus at 3 months 
and one (1.4%) died within the 30 day period due to 
respiratory insufficiency. No cause of death was aneurysm- 
related in this study.
Table 3 shows an overview of the medication and number 
of complications. All patients (n=70) used thrombocyte 
aggregation inhibitors (ASA 80-100mg) by protocol. Other 
frequently used medication were
P-blockers (49%), RAS inhibitors (44%), coumarin- 
derivatives (43%). The in-hospital medication consisted of 
analgesics (36%), lipid-lowering drugs (23%), anti-emetics 
(29%) and calcium-antagonists (23%) respectively.
Patients who used analgesics during hospital stay (36%) 
showed more device related complications (P= 0.01) 
compared to patients who did not used this drug during 
hospital stay. Patients using anti-emetic drugs during 
hospital-stay (29%) showed more non-device-related 
complications (P= 0.036) compared to non-users. Patients 
who used coumarin-derivatives showed less non-device- 
related complications (P= 0.035) compared to non-users. The 
grade of severity of complications is presented in Table 4.
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Table 2. Overview of complications
Complications*
Device Related 24 (3ó%) Non-Device Related 43 (ó4%)
Stent Migration 3 (4%) Stroke 9 (13%)
Stent Occlusion 5 (7%) Myocardial infarction 7 (10%)
Endoleak type I 8 (12%) Pulmonary embolus 9 (13%)
Endoleak type II 4 (ó%) Other / Unspecified 18 (27%)
Endoleak type III 4 (ó%)
Endoleaks unspecified 4 (ó%)
Rupture 0
* N= 67 complications (in 41 patients)
Table 3. Overview: medication variables and number of complications.
Medication type Use 
n (%)
Device 
related 
n (%)
Complications
P-value
Non-device 
related 
n (%) P-value
Coumarin derivative 30 (43) 12 (40) .120 4 (13) .035
Lipid lowering 23 (33) 5 (22) .120 4 (17) .952
?-Blocker 34 (49) 9 (27) .310 9 (27) .895
RAS inhibitor 31(44) 10 (32) .775 9 (29) .930
Loop diuretic 12 (17) 3 (25) .377 3 (25) .940
Thiazide diuretic 10 (14) 1 (10) .201 3 (30) .3ó0
Calcium antagonist 1ó (23) 7 (44) .321 5 (31) .7ó9
Proton-pump inhibitor 13 (19) 4 (31) .897 5 (39) .111
Analgesics in hospital 25 (3ó) 14 (5ó) .010 7 (28) .813
Anti-emetics in hospital 20 (29) 5 (25) .052 7 (35) .03ó
Opioids in hospital 13 (19) 3 (23) .274 4 (31) .774
Other* 27 (39) 11(41) N/A 5 (19) N/A
All patients 70 25 (3ó) 1ó (23)
* = Immunosuppressive drugs, Anti-histaminic, Laxative, Heart-glycoside, Tranquillizers, Hormones, Anti-gout, Anti-diabetics, Action­
potential enlarger, Anti-conceptive, Folic acid and Inhaling drugs
Table 4. Overview: medication variables and classification of complications
Medication type Use 
n (%)
Mild
n (%) P-value
Complications 
Moderate 
n (%) P-value
Severe 
n (%) P-value
Coumarin derivative 30 (43) 7 (23) 0.312 12 (40) 0.135 0 (0) 0.940
Lipid lowering drug 23 (33) 4 (17) 0.83ó 5 (22) 0.158 1 (4) 0.9ó3
?-Blocker 34 (49) 4 (12) 0.173 9 (27) 0.155 4 (12) 0.9ó1
RAS inhibitor 31 (44) ó (19) 0.28ó 11 (3ó) 0.541 3 (10) 0.871
Loop diuretic 12 (17) 2 (17) 0.ó02 2 (17) 0.959 2 (17) 0.9ó3
Thiazide diuretic 10 (14) 2 (20) 0.295 0 (0) 0.957 1 (10) 0.978
Calcium antagonist 1ó (23) 5 (31) 0.252 7 (44) 0.1óó 3 (19) 0.758
Proton-pump inhibitor 13 (19) 3 (23) 0.512 4 (31) 0.893 1 (8) 0.904
Analgesics in hospital 25 (3ó) 8 (32) 0.0ó8 10 (40) 0.274 2 (8) 0.2ó5
Anti-emetics in hospital 20 (29) 4 (20) 0.474 8 (40) 0.213 1 (5) 0.991
Opioids in hospital 13 (19) 4 (31) 0.35ó 2 (15) 0.232 2 (15) 0.48ó
Other* 27 (19) 5 (19) N/A 8 (30) N/A 4 (15) N/A
All patients 70 14 (20) 23 (33) 7 (10)
* = Immunosuppressive drugs, Anti-histaminic, Laxative, Heart-glycoside, Tranquillizers, Hormones, Anti-gout, Anti-diabetics, Action­
potential enlarger, Anti-conceptive, Folic acid and Inhaling drugs.
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DISCUSSION
Presently, little is known about the influence of 
medication on the occurrence of complications after 
endovascular aneurysm repair (EVAR), whereas recognizing 
certain patterns in pathology and causes of complications 
is important [12,13] . As delivery and stent-graft systems 
have improved and are fairly standardized [6,14,15], risk 
profiles such as co-morbidity and medication are becoming 
more important factors for making evidence based decisions 
concerning elective endovascular therapy in patients with 
an aneurysm of the abdominal aorta (AAA) [6]. It is also 
important to detect whether in the post-operative period 
the risks for developing complications might be diminished. 
When more patient-related factors will be identified, 
appropriate alternatives in follow-up or medication may be 
developed. This study was designed to investigate whether 
additional medication is associated with any risk of 
complications in AAA-patients after EVAR.
The EVAR population consists of cardiovascular 
patients [16-18]. The preventive effect of thrombocyte- 
aggregation inhibitors in this population is already proven 
and therefore implemented in the EVAR-protocol [12,19-21]. 
Many cardiovascular patients are using coumarin- 
derivatives on a daily basis besides standard acetylsalicylic 
acid [3,12,19]. In our population the use ofboth thrombocyte 
aggregation inhibitors (by protocol) and coumarin- 
derivatives was quite common (e.g. 43%). This combination 
provides a protective effect against acute vascular events 
[5,20]. There are different opinions about the use of 
coumarin-derivatives next to thrombocyte-aggregation 
inhibitors after a device implant. Because of the anti­
thrombotic effect of coumarin-derivatives [5] it was expected 
that more endoleaks could occur because of the occurence 
of a hyperthrombenemic state. This could not be confirmed 
in the present study. Patients using coumarin-derivatives in 
this study had less non-device-related complications than 
patients who did not.The use of analgesics during hospital 
stay was associated with significantly more device-related 
complications.
Patients using anti-emetic drugs during hospital-stay 
had more non-device-related complications. We have no 
explanation for these outcomes.
The mortality rate of 1.4% in the present study 
population is comparable to those of the EVAR-1 trial and 
the DREAM trial [22-24]. In these studies a mortality rate of 
2.7% and 3% was recorded for elective EVAR. The initial 
survival advantage over open aneurysm repair, however, 
was not sustained after the first postoperative year. The 
main cause of late postoperative death in both trials was 
cardiovascular, confirming the impact of comorbidity in EVAR 
patients.
The EVAR-2 study was conducted in patients unfit for 
open aneurysm repair. It showed that EVAR is not a safe 
procedure in such high-risk patients [23]. It also raised 
concern about the medical treatment of these patients, 
fuelling the attention for co-morbidity and medication.
In conclusion, medication seems to be associated with 
the occurrence of complications following endovascular 
therapy of abdominal aortic aneurysms. Patients on 
coumarin-derivatives experienced fewer non-device-related 
complications. Patients who used anti-emetic drugs during 
hospital-stay showed a fourfold number of non-device- 
related complications. Patients using analgesics during 
hospital stay were associated with significantly more device­
related complications.
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